Effective PROTAC design is a coupled optimization problem. Each choice changes the ternary-complex ensemble, intracellular exposure, selectivity, and degradation kinetics—so component decisions must be made together.
Define the disease context, depletion depth, kinetics, and the effect expected from removing the full protein.
Choose for cellular engagement and attachment tolerance, not affinity alone, and test several exit vectors.
Pick an active cellular system in the right compartment, not merely an available recruiter.
Sample geometry and molecular properties together across length, flexibility, polarity, and rigidity.
Vary exit vector, ligase, linker, and stereochemistry to separate the likely failure modes.
The most useful starting set is not the largest one. It varies a few high-impact decisions—warhead exit vector, ligase recruiter, linker architecture, and ternary geometry—so each experimental outcome points to a specific redesign strategy.
The warhead should bind the intended target in the relevant conformation and compartment. Intracellular engagement, selectivity, residence time, and free exposure matter more than biochemical affinity alone.
VHL and CRBN are common because ligands and structures exist, but familiarity does not guarantee suitability. Evaluate expression, localization, complex assembly, genetic dependency, and normal-tissue distribution.
Length is only one variable. Composition, flexibility, branching, polarity, rigidity, stereochemistry, and directionality all influence the conformational ensemble and exposure.
A single endpoint such as DC50 cannot explain why a compound works or fails. The cascade connects compound quality, engagement, ternary formation, degradation, function, and selectivity.
Discuss Your Study DesignIdentity, purity, solubility, aggregation risk, stability, and permeability protect downstream interpretation.
Binary affinity and cellular engagement show whether the conjugate retained useful binding.
Use concentration matrices and orthogonal formats to assess cooperativity, kinetics, and hook behavior.
Include time courses, degradation depth, recovery, proteasome rescue, and ligase dependence.
Use target-proximal biomarkers, resistant rescue, and matched viability controls.
Quantitative proteomics and intracellular concentration distinguish molecular recognition from delivery.
| Variable | Recommended variation | Question answered |
|---|---|---|
| Target exit vector | Two or more positions supported by SAR or structural models | Can the ligase approach productive target surfaces? |
| E3 system | One validated recruiter; a second ligase if biology supports it | Is failure ligase-specific? |
| Linker length | Short, intermediate, and longer representatives | Which distance range permits ternary formation? |
| Linker character | Flexible/polar versus more rigid or lipophilic analogs | Are geometry and exposure changing together? |
| Stereochemistry | Active and recruiter-impaired stereochemical controls where possible | Is degradation dependent on intended ligase binding? |
| Controls | Warhead, recruiter, nonbinding analog, and competition conditions | Which component and pathway are required? |
Confirm that loss of the full protein is the intended intervention, then establish the constraints that keep chemistry from optimizing toward an irrelevant endpoint.
A compound with a low DC50 but incomplete Dmax, poor solubility, broad proteomic effects, or no functional separation from toxicity is not automatically the best lead.
Record structures, stereochemistry, salt forms, purity, and analytical conditions.
Specify constructs, tags, assay orientation, concentrations, and fitting models.
Report replicates, time points, Dmax, DC50, recovery, and unbound exposure.
Retain alternative ternary models and track negative data that define the design space.
The authors revealed that favorable protein–protein contacts and linker folding can create cooperative recognition in the VHL–MZ1–BRD4 complex, linking ternary architecture to selective degradation.
The authors demonstrated catalytic, event-driven protein knockdown, establishing that substoichiometric degradation—rather than target occupancy—is the design goal that matters for potency.
The right first move depends on which component is best defined—these answers clarify where to start.
There is no universal number. The first set should cover distinct geometric and property hypotheses across length, composition, rigidity, and exit vector while remaining synthetically manageable. A diverse, interpretable matrix is more valuable than many closely related linkers that sample the same conformational space.
Sometimes. Favorable ternary contacts and event-driven pharmacology can compensate for modest binary affinity. Nevertheless, the conjugate must achieve sufficient cellular engagement and exposure. Weak affinity should not be used to explain every successful result without measured ternary formation and target engagement.
Identify its limiting dimension before expanding chemistry. The next cycle may need greater selectivity, deeper degradation, faster onset, better recovery behavior, improved permeability or solubility, reduced efflux, metabolic stability, or a simpler synthesis. Optimizing only DC50 can move the program away from a balanced lead profile.
Share the target, available ligands, preferred E3 systems, structural data, assays, and project constraints. CD ComputaBio will propose a fit-for-purpose design scope. Related services: PROTAC Design and Development Service, PROTAC Linker Design & Optimization, Molecular Dynamics Simulation.
Submit your project details below, and our team will respond within 24 hours.
Talk to our technical team about your project!
I Want To Talk
